SEC Company Response from ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858) (ACHV) — Nov 19, 2015
ACHIEVE LIFE SCIENCES, INC. (ACHV) (CIK 0000949858)
Date: Nov. 19, 2015 · CIK: 0000949858 · Accession: 0001193125-15-382110
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207670
Letter
ONCOGENEX PHARMACEUTICALS, INC
19820 North Creek Parkway
Bothell, Washington 98011
(425) 686-1500
November 19, 2015
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C.
Attention:
Suzanne Hayes
Scot Foley
Division of Corporation Finance
Re:
OncoGenex Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 29, 2015
File No. 333-207670
Via EDGAR - Acceleration Request
Requested Date:
November 20, 2015
Requested Time:
4:00 p.m. EST
Ladies and Gentlemen:
OncoGenex Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
ONCOGENEX PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ONCOGENEX PHARMACEUTICALS, INC 19820 North Creek Parkway Bothell, Washington 98011 (425) 686-1500 November 19, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Scot Foley Division of Corporation Finance Re: OncoGenex Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed October 29, 2015 File No. 333-207670 Via EDGAR - Acceleration Request Requested Date: November 20, 2015 Requested Time: 4:00 p.m. EST Ladies and Gentlemen: OncoGenex Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-referenced Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, ONCOGENEX PHARMACEUTICALS, INC. By: /s/ John Bencich John Bencich Chief Financial Officer